Generation and optimization of a chimeric antigen receptor against human CD22: A new immunotherapeutic agent for adoptive immunotherapy

被引：0
|
作者：
Haso, Waleed [1 ]
Lee, Daniel [1 ]
Morgan, Richard [1 ]
Pastan, Ira [1 ]
Mackall, Crystal [1 ]
Orentas, Rimas J. [1 ]
机构：
[1] NIH, Bethesda, MD 20892 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-3504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3504
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy
    Bhoj, Vijay
    Milone, Michael C.
    June, Carl H.
    Porter, David
    Grupp, Stephan A.
    Melenhorst, Jan J.
    Lacey, Simon F.
    Callahan, Colleen
    Capobianchi, James
    Wertheim, Gerald
    Mahnke, Yolanda
    BLOOD, 2014, 124 (21)
  • [42] CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
    Till, Brian G.
    Jensen, Michael C.
    Wang, Jinjuan
    Qian, Xiaojun
    Gopal, Ajay K.
    Maloney, David G.
    Lindgren, Catherine G.
    Lin, Yukang
    Pagel, John M.
    Budde, Lihua E.
    Raubitschek, Andrew
    Forman, Stephen J.
    Greenberg, Philip D.
    Riddell, Stanley R.
    Press, Oliver W.
    BLOOD, 2012, 119 (17) : 3940 - 3950
  • [43] Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract
    Zeng, Chen
    Cheng, Jiali
    Li, Tongjuan
    Huang, Jin
    Li, Chunrui
    Jiang, Lijun
    Wang, Jue
    Chen, Liting
    Mao, Xia
    Zhu, Li
    Lou, Yaoyao
    Zhou, Jianfeng
    Zhou, Xiaoxi
    CYTOTHERAPY, 2020, 22 (03) : 166 - 171
  • [44] Generation and characterization of a new chimeric human/mouse anti-Idiotype antibody ganglidiximab for active immunotherapy against neuroblastoma
    Eger, C.
    Siebert, N.
    Seidel, D.
    Zumpe, M.
    Juettner, M.
    Lode, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 65 - 65
  • [45] CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study
    Hu, Yongxian
    Zhang, Yanlei
    Zhao, Houli
    Wang, Yiyun
    Nagler, Arnon
    Chang, Alex Hong
    Huang, He
    BLOOD, 2020, 136
  • [46] Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials
    Xu, Xiao-Jun
    Zhao, Hai-Zhao
    Tang, Yong-Min
    LEUKEMIA & LYMPHOMA, 2013, 54 (02) : 255 - 260
  • [47] A New Specific Promoter Allow Hematopoietic Stem Cell Immunotherapy Approach Against Acute Lymphoblastic Leukemia Using Chimeric Antigen Receptor
    Colamartino, Aurelien
    Bifsha, Panojot
    Colas, Chloe
    Tremblay-Laganiere, Camille
    Nicoletti, Simon
    Guiot, Melanie
    Boldici, Andrei
    Li, Yuanyi
    Haddad, Elie
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [48] Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia
    Xue, Tongyuan
    Del Real, Marissa
    Marcucci, Emanuela
    Toribio, Candida
    Setayesh, Sonia Maryam
    Forman, Stephen J.
    Horne, David A.
    Budde, Lihua E.
    BLOOD, 2019, 134
  • [49] Human CD4+CD25+T cells expressing a chimeric antigen receptor against aberrant superoxide dismutase 1 trigger antigen-specific immunomodulation
    Graber, David J.
    Cook, W. James
    Murad-Mabaera, Joana M.
    Sentman, Charles L.
    CYTOTHERAPY, 2024, 26 (02) : 126 - 135
  • [50] Safety and Efficacy of CD22 and CD19 Chimeric Antigen Receptor T Cell Treatment Bridging to Autologous Stem Cell Transplantation As Consolidation Therapy for B-Cell Acute Lymphoblastic Leukemia
    Qiu, Yan
    Qian, Chong-Sheng
    Zhou, Hai-Xia
    Xu, Ming-Zhu
    Kang, Li-Qing
    Sun, Ai-Ning
    Wu, De-Pei
    Yu, Lei
    Xue, Shengli
    BLOOD, 2022, 140 : 10337 - 10338
12345